两种阿奇霉素序贯治疗方案治疗儿童支原体肺炎的疗效比较

目的：比较两种阿奇霉素序贯治疗方案治疗儿童支原体肺炎的疗效及安全性。方法：将76例儿童支原体肺炎患儿随机均分为观察组和对照组。观察组患儿给予注射用阿奇霉素10mg／（kg·d），静脉滴注，qd，连续给药3d，停用4d，更换为阿奇霉素肠溶胶囊10mg／（kg·d），qd，口服，连续给药3d，停用4d；对照组患儿给予注射用阿奇霉素10mg／（kg·d），静脉滴注，qd，连续给药5d，停用2d，更换为阿奇霉素肠溶胶囊10mg／（kg·d），qd，口服，连续给药5d，停用2d。两组患儿的疗程均为14d。比较两组患儿的临床疗效；记录所有患儿退热时间、咳嗽好转时间、肺部哆音消失时间、平均住院时间及不良反应发生情况。结果：两组患儿的总有效率、退热时间、咳嗽好转时间、肺部哆音消失时间及平均住院时间比较，差异均无统计学意义（P〉0.05）；观察组患儿不良反应发生率显著低于对照组，两组比较差异有统计学意义（P〈0.05）。结论：阿奇霉素采用给药3d停4d的序贯疗法治疗儿童支原体肺炎更安全，患儿依从性更好。

Analysis of the Efficacy of 2 Models of Azithromycin Sequential Therapy in Treatment of Child Mycoplasma Pneumonia

OBJECTIVE： To compare clinical efficacy and safety of sequential therapy of 2 dosage forms of azithromycin in the treatment of child mycoplasma pneumonia. METHODS： 76 children with mycoplasma pneumonia were randomized into observation group and control group. Observation group was given azithromycin 10 mg/（kg·d） intravenously, once a day for 3 days, followed by 4-day interval, and then treated with Azithromycin enteric capsule 10 mg/（kg· d） orally, once a day for 3 days, followed by 4-day interval. Control group was given Azithromycin for injection 10 mg/（kg· d） intravenously, once a day for 5 days, followed by 2-day interval, and then treated with Azithromycin enteric capsule 10 mg/（kg·d） orally, once a day for 5 days, followed by 2-day interval. Treatment course of 2 groups lasted for 14 days. Clinical efficacy of all patients was evaluated, and the time of abatement of fever, cough and pulmonary rales disappearance, the duration of hospitalization, the occurrence of ADR were recorded. RESULTS： There was no significant difference between 2 groups in total effective rate, the abatement of fever, cough and pulmonary rales disappearance, the duration of hospitalization （P〉0.05）. The incidence of adverse drug reaction in observation group was significantly lower than in control group; there was statistical significance （P〈0.001）. CONCLUSIONS： The （3-day treatment followed by a 4-day interval） of sequential therapy of azithromycin is more safety and effective in the treatment of child mycoplasma pneumonia, and can improve compliance of patient.